Garlick P B, Mashiter G D, Di Marzo V, Tippins J R, Morris H R, Maisey M N
Department of Radiological Sciences, United Medical School of Guy's Hospital, Guy's Campus, London Bridge, UK.
J Mol Cell Cardiol. 1989 Nov;21(11):1101-10. doi: 10.1016/0022-2828(89)90688-3.
When the perfusion medium of an isolated, non-recirculating, Langendorff rat heart is changed from Krebs buffer to coronary effluent, a significant vasoconstriction (23%, P less than 0.005) is observed. In this study we have investigated the involvement of leukotrienes in this phenomenon. We have extracted and quantified leukotrienes C4, D4 and E4 in samples of coronary effluent taken at different times during the first 2 h of perfusion; the total amounts released during this time were 9, 5 and 32 pmol of LTC4, LTD4 and LTE4 respectively. We have used two different methods to prevent the action of the effluent leukotrienes on the heart. Firstly, we have blocked the leukotriene receptors in the heart, with FPL 55712 (3.8 microM), during perfusion with effluent and, secondly, we have perfused with coronary effluent which was collected in the presence of a leukotriene synthesis inhibitor, AA861 (1 microM). The addition of FPL 55712 to the effluent decreased the normally observed vasoconstriction such that after 30 min the coronary flow rate (CFR) was 114 +/- 3% (n = 6) compared with 66 +/- 1% (n = 7) with effluent alone (P less than 0.005). Effluent collected in the presence of AA861 also caused a decrease in the normally observed vasoconstriction such that by 30 min the CFR was still 88 +/- 2% (n = 6, P less than 0.005 compared to controls). We have confirmed the proposed involvement of leukotrienes in the effluent-induced vasoconstriction by investigating the effect of a mixture of the synthetic leukotrienes C4, D4 and E4, when each of them was present at the same concentration as measured in the coronary effluent; the vasoconstriction observed was superimposable upon that seen with effluent. This vasoactive effect of the leukotriene mixture was not secondary to a change in contractility, since this only decreased to 97 +/- 5% (n = 9) during the 30 min of the leukotriene infusion. Finally, we have studied the effects of the same two leukotriene blockers in normal, buffer-perfused hearts after an initial perfusion of either 30 or 120 min. Application of either AA861 or FPL 55712 resulted in a dramatic vasodilatation (25 to 45% increase), a larger effect always being observed after the shorter initial period of perfusion. Our conclusions are two-fold. Firstly, isolated, buffer-perfused rat hearts synthesize leukotrienes C4, D4 and E4 in considerable amounts and release them into the coronary effluent and secondly, the coronary flow rates of isolated, buffer-perfused rat hearts are partly controlled by the action of internally produced leukotrienes.
当将离体、非循环的Langendorff大鼠心脏的灌注介质从Krebs缓冲液更换为冠脉流出液时,可观察到显著的血管收缩(23%,P<0.005)。在本研究中,我们调查了白三烯在这一现象中的作用。我们在灌注的最初2小时内不同时间采集冠脉流出液样本,提取并定量其中的白三烯C4、D4和E4;这段时间内释放的总量分别为9、5和32皮摩尔的LTC4、LTD4和LTE4。我们使用了两种不同方法来阻止流出液中的白三烯对心脏的作用。首先,在灌注流出液期间,我们用FPL 55712(3.8微摩尔)阻断心脏中的白三烯受体;其次,我们用在白三烯合成抑制剂AA861(1微摩尔)存在下收集的冠脉流出液进行灌注。向流出液中添加FPL 55712可降低通常观察到的血管收缩,使得30分钟后冠脉流速(CFR)为114±3%(n=6),而单独使用流出液时为66±1%(n=7)(P<0.005)。在AA861存在下收集的流出液也导致通常观察到的血管收缩减少,使得30分钟时CFR仍为88±2%(n=6,与对照组相比P<0.005)。我们通过研究合成白三烯C4、D4和E4的混合物的作用,证实了白三烯参与流出液诱导的血管收缩,当它们各自的浓度与冠脉流出液中测得的浓度相同时;观察到的血管收缩与用流出液时所见的血管收缩叠加。白三烯混合物的这种血管活性作用并非继发于收缩性的改变,因为在白三烯输注的30分钟内收缩性仅降至97±5%(n=9)。最后,我们研究了在最初灌注30或120分钟后,相同的两种白三烯阻断剂对正常、缓冲液灌注心脏的影响。应用AA861或FPL 55712均导致显著的血管扩张(增加25%至45%),在较短的初始灌注期后总是观察到更大的效应。我们的结论有两点。首先,离体、缓冲液灌注的大鼠心脏大量合成白三烯C4、D4和E4并将其释放到冠脉流出液中;其次,离体、缓冲液灌注的大鼠心脏的冠脉流速部分受内源性产生的白三烯的作用控制。